261 related articles for article (PubMed ID: 24038728)
21. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy.
Farrell LJ; Waters AM; Boschen MJ; Hattingh L; McConnell H; Milliner EL; Collings N; Zimmer-Gembeck M; Shelton D; Ollendick TH; Testa C; Storch EA
Depress Anxiety; 2013 Aug; 30(8):723-31. PubMed ID: 23722990
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
[TBL] [Abstract][Full Text] [Related]
23. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.
Mataix-Cols D; Fernández de la Cruz L; Monzani B; Rosenfield D; Andersson E; Pérez-Vigil A; Frumento P; de Kleine RA; Difede J; Dunlop BW; Farrell LJ; Geller D; Gerardi M; Guastella AJ; Hofmann SG; Hendriks GJ; Kushner MG; Lee FS; Lenze EJ; Levinson CA; McConnell H; Otto MW; Plag J; Pollack MH; Ressler KJ; Rodebaugh TL; Rothbaum BO; Scheeringa MS; Siewert-Siegmund A; Smits JAJ; Storch EA; Ströhle A; Tart CD; Tolin DF; van Minnen A; Waters AM; Weems CF; Wilhelm S; Wyka K; Davis M; Rück C; ; Altemus M; Anderson P; Cukor J; Finck C; Geffken GR; Golfels F; Goodman WK; Gutner C; Heyman I; Jovanovic T; Lewin AB; McNamara JP; Murphy TK; Norrholm S; Thuras P
JAMA Psychiatry; 2017 May; 74(5):501-510. PubMed ID: 28122091
[TBL] [Abstract][Full Text] [Related]
24. [Short-term effects of a cognitive-behavioural group therapy in social phobia: evaluation of sixty patients].
Camart N; André C; Trybou V; Bourdel MC
Encephale; 2006; 32(6 Pt 1):1011-8. PubMed ID: 17372547
[TBL] [Abstract][Full Text] [Related]
25. Social phobia: maintenance models and main components of CBT.
Marom S; Aderka IM; Hermesh H; Gilboa-Schechtman E
Isr J Psychiatry Relat Sci; 2009; 46(4):264-8. PubMed ID: 20635773
[TBL] [Abstract][Full Text] [Related]
26. D-Cycloserine augmentation of cognitive behavior therapy for pediatric OCD: Predictors and moderators of outcome.
Wilhelm S; Berman N; Small BJ; Porth R; Storch EA; Geller D
J Affect Disord; 2018 Dec; 241():454-460. PubMed ID: 30149332
[TBL] [Abstract][Full Text] [Related]
27. Fear extinction learning as a predictor of response to cognitive behavioral therapy for pediatric obsessive compulsive disorder.
Geller DA; McGuire JF; Orr SP; Small BJ; Murphy TK; Trainor K; Porth R; Wilhelm S; Storch EA
J Anxiety Disord; 2019 May; 64():1-8. PubMed ID: 30852257
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.
Durham RC; Chambers JA; Power KG; Sharp DM; Macdonald RR; Major KA; Dow MG; Gumley AI
Health Technol Assess; 2005 Nov; 9(42):1-174. PubMed ID: 16266559
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic relationship in cognitive-behavioral therapy and pharmacotherapy for anxious youth.
Cummings CM; Caporino NE; Settipani CA; Read KL; Compton SN; March J; Sherrill J; Piacentini J; McCracken J; Walkup JT; Ginsburg G; Albano AM; Rynn M; Birmaher B; Sakolsky D; Gosch E; Keeton C; Kendall PC
J Consult Clin Psychol; 2013 Oct; 81(5):859-64. PubMed ID: 23750468
[TBL] [Abstract][Full Text] [Related]
30. A high-throughput clinical assay for testing drug facilitation of exposure therapy.
Rodebaugh TL; Levinson CA; Lenze EJ
Depress Anxiety; 2013 Jul; 30(7):631-7. PubMed ID: 23283838
[TBL] [Abstract][Full Text] [Related]
31. Extinction learning as a moderator of d-cycloserine efficacy for enhancing exposure therapy in posttraumatic stress disorder.
de Kleine RA; Smits JA; Hendriks GJ; Becker ES; van Minnen A
J Anxiety Disord; 2015 Aug; 34():63-7. PubMed ID: 26121495
[TBL] [Abstract][Full Text] [Related]
32. Cognitive reappraisal self-efficacy mediates the effects of individual cognitive-behavioral therapy for social anxiety disorder.
Goldin PR; Ziv M; Jazaieri H; Werner K; Kraemer H; Heimberg RG; Gross JJ
J Consult Clin Psychol; 2012 Dec; 80(6):1034-40. PubMed ID: 22582765
[TBL] [Abstract][Full Text] [Related]
33. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder.
Wilhelm S; Buhlmann U; Tolin DF; Meunier SA; Pearlson GD; Reese HE; Cannistraro P; Jenike MA; Rauch SL
Am J Psychiatry; 2008 Mar; 165(3):335-41; quiz 409. PubMed ID: 18245177
[TBL] [Abstract][Full Text] [Related]
34. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder.
Storch EA; Murphy TK; Goodman WK; Geffken GR; Lewin AB; Henin A; Micco JA; Sprich S; Wilhelm S; Bengtson M; Geller DA
Biol Psychiatry; 2010 Dec; 68(11):1073-6. PubMed ID: 20817153
[TBL] [Abstract][Full Text] [Related]
35. Hydrocortisone as an adjunct to brief cognitive-behavioural therapy for specific fear: Endocrine and cognitive biomarkers as predictors of symptom improvement.
Steudte-Schmiedgen S; Fay E; Capitao L; Kirschbaum C; Reinecke A
J Psychopharmacol; 2021 Jun; 35(6):641-651. PubMed ID: 33908295
[TBL] [Abstract][Full Text] [Related]
36. Psychotherapy in the overall management strategy for social anxiety disorder.
Shear MK; Beidel DC
J Clin Psychiatry; 1998; 59 Suppl 17():39-46. PubMed ID: 9811429
[TBL] [Abstract][Full Text] [Related]
37. [Clinical and therapeutic characteristics of social phobia in French psychiatry (Phoenix study)].
Pélissolo A; Huron C; Fanget F; Servant D; Stiti S; Richard-Berthe C; Boyer P
Encephale; 2006; 32(1 Pt 1):106-12. PubMed ID: 16633297
[TBL] [Abstract][Full Text] [Related]
38. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.
Davidson JR; Foa EB; Huppert JD; Keefe FJ; Franklin ME; Compton JS; Zhao N; Connor KM; Lynch TR; Gadde KM
Arch Gen Psychiatry; 2004 Oct; 61(10):1005-13. PubMed ID: 15466674
[TBL] [Abstract][Full Text] [Related]
39. Randomized controlled trial of cognitive behavioral therapy and acceptance and commitment therapy for social phobia: outcomes and moderators.
Craske MG; Niles AN; Burklund LJ; Wolitzky-Taylor KB; Vilardaga JC; Arch JJ; Saxbe DE; Lieberman MD
J Consult Clin Psychol; 2014 Dec; 82(6):1034-48. PubMed ID: 24999670
[TBL] [Abstract][Full Text] [Related]
40. Change in quality of life and their predictors in the long-term follow-up after group cognitive behavioral therapy for social anxiety disorder: a prospective cohort study.
Watanabe N; Furukawa TA; Chen J; Kinoshita Y; Nakano Y; Ogawa S; Funayama T; Ietsugu T; Noda Y
BMC Psychiatry; 2010 Oct; 10():81. PubMed ID: 20942980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
